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Abstract. Background: Anemia of chronic kidney disease (CKD) has been traditionally treated by erythropoiesis-stimulating
agents (ESAs) and/or iron following manual
determination of dose. We hypothesized that
once-monthly (QM) algorithmically dosed

       
would successfully treat anemia of CKD in
ESA-naïve CKD subjects. Methods: QM DA
and iron doses were determined via a computerized program targeting a hemoglobin
(Hb) of 10.5 – 12.5 g/dl in anemic, ESA-naïve, CKD Stages 3 – 5 subjects. Six consecutive QM doses were administered. Hb, ferritin, and transferrin saturation were recorded.
Data are presented as means ± standard deviation. Results:      
133 subjects, with a mean follow-up of 188
          
greater at Months 3 and 6 compared to baseline (p < 0.05); DA doses were 109 ± 68 μg
and 118 ± 91, respectively, at Months 3 and
6. Hemoglobin levels were correspondingly
11.3 ± 1.1 g/dl and 11.3 ± 1.0. 78% of patients achieved the target Hb by 6 months of
therapy. The elevation of Hb was greater in
non-proteinuric than proteinuric subjects at
6 months of treatment (11.6 ± 0.8 g/dl vs.
11.0 ± 1.1; p < 0.05), despite lower DA dose
(96 ± 76 μg vs. 139 ± 98; p < 0.05). Conclusion: Successful treatment of the anemia of
CKD by QM DA based upon a computerized
dosing program was achieved by 6 months in
78% of ESA-naïve, CKD subjects.

Introduction
Anemia is common feature in chronic
kidney disease (CKD) and progresses with
deterioration of kidney function [1]. Effective treatment for anemia in CKD is available
and consists of iron supplementation and
erythropoiesis-stimulating agents (ESA) [2,
3, 4]. Despite the availability of these agents,
treatment of anemia is often suboptimal from

implementation and outcomes standpoints
[5, 6, 7]. Only one-third of CKD patients
were reported as receiving ESA therapy at
the onset of ESRD with a mean hemoglobin
(Hb) of 10.2 g/dl [8]. In non-dialysis CKD
patients, progressive lengthening of the ESA
dosing interval has occurred during the past
   
  
from several weekly doses to weekly doses
!"   
    istered weekly or bi-weekly. More recently,
    #      $
of even longer ESA dosing intervals, i.e., every 4 weeks [10, 11, 12, 13, 14, 15, 16, 17,
18, 19].
Although QM DA dosing trials have doc&  $   
  #
between 10 and 13 g/dl in patients previously
treated with more frequent dosing regimens,
the issue of patient selection for “responsiveness” to ESA is notable [17, 18, 19]. First,
subjects were required to have a stable Hb
within the target range during the pre-existing regimen and often, an iron replete state
was required. Therefore, the selection of
ESA-responsive patients is not immediately
generalizable and transferable to real world
practice where there is heterogeneity of iron
&$  " '      * '
dosing intervals. Moreover, published clini   #     +  &      
for conversion from EA to DA, without the
  $ &         
support system. Often, a bodyweight-based
system of ESA dosing was employed. In addition, the erythropoietic environment was
usually optimized in advance of conversion
to DA from EA by excluding individuals
       *   
=       
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We hypothesized that management of
the anemia of CKD in ESA-naïve patients
could be achieved with an automated algorithm that employed the longer-acting ESA,
darbepoetin. As the primary objective of this
study, we determined the proportion of ESAnaïve subjects who could attain a target Hb of
10.5 – 12.5 g/dl by Month 6 of DA treatment,
in a broadly based outpatient clinic population, using such an algorithm. A secondary
objective of this study was determination
of the effects of diabetes and proteinuria on
anemia treatment outcomes.

Methods
Study design: A retrospective analysis
was conducted on all patients being initiated
on treatment for anemia of CKD at the Nephrology and Hypertension clinic at Henry
Ford Health System, Detroit MI between
5/2005 and 7/2007. The Nephrology and
Hypertension clinic is multidisciplinary and
$        >  " 
903-bed urban medical center, located in Detroit, MI. In addition to regular follow-up by
a nephrologist, the patients were seen on-site
by dietitians, social workers and mid-level
providers in order to provide comprehensive
CKD management.
We implemented an automated, web        $
the nephrology clinic. The algorithm uses
trend analysis of Hb and DA dose as well
iron parameters to determine QM DA and
iron supplementation if indicated. Approval
for retrospective analysis of data was granted
by our local research review committee. In
addition to the primary objective, fraction of
patients achieving target Hb between 10.5
and 12.5 g/dl by 6 months of therapy, we also
determined the effect of proteinuria and diabetes on DA dose, Hb, transferrin saturation
(TSAT) and ferritin responses with QM DA
and iron therapy.
The study population consisted of all
CKD 3 – 5 patients that initiated de novo QM
DA for treatment for anemia of CKD, and received 6 consecutive doses between 05/2005
and 07/2007. Exclusionary criteria included
organ transplantation recipient status, ongoing immunosuppressive therapy or the

2
need for hemodialysis or peritoneal dialysis
  ?   $    @#"
133 patients met the inclusion criteria. Time
elapsed between two consecutive DA doses
was no less than 20 days and no longer than
45 days. We did not exclude iron deplete patients, or patients with comorbid conditions
that might affect ESA response.
        $ G JLP *
on two or more separate readings at least 1
    UV '      
X   $  
Y    Z>Y
Equation 4 based on the serum creatinine
level at the time of the visit preceding initiation of ESA treatment [20, 21]. The following data for all patients meeting inclusion/
exclusion criteria was retrieved for analysis
at the time of the CKD clinic visit preceding
initiation of ESA therapy: ethnicity, gender,
diabetic status, CKD stage and the presence
or absence of proteinuria on routine urinalysis. Blood pressure (BP), Hb, serum iron,
transferrin saturation (TSAT), serum ferritin,
and DA dose were determined monthly. Etiology of CKD, age, body weight (kg), and
use of angiotensin converting enzyme inhibitors (ACEI) or angiotensin receptor blockers
Y^    _   $ UV
was determined by the evaluating nephrologist and included primarily hypertensive
angiosclerosis (43.7%), Type 2 diabetic nephropathy (22.6%) or a combination of both
(12.9%). Other diagnoses included a prerenal state (4.7%), chronic glomerulonephritis (2.4%), incomplete recovery from ATN
(1.6%), HIV-associated nephropathy (1.6%),
and unknown diagnoses (5.3%).
The Computerized Anemia Management
Program (CAMP©) is a pair of proprietary,
network-distributed DA and iron treatment
algorithms. The same iron and DA dosing algorithms were applied in all patients.
CAMP© is designed to treat the anemia of
CKD by querying a database that includes
continuous quality initiatives. After initial
data input, CAMP© calculates an iron dosing strategy based upon ferritin, TSAT and
Hb levels and prescribes either no iron, oral
iron (Nephron FA® or ferrous sulfate) or intravenous iron (Figure 1). CAMP© employs
    $   "    
maintenance (dose 3 and afterward) monthly
  _        try Hb: a) Hb < 9 g/dl, 200 μg, b) Hb 9.0 and
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 ! "    #!
Hb0     
  $ 
 #! %&%   $       !
$  #

< 10.5 g/dl, 100 μg and c) Hb 10.5 g/dl, 60 μg.
The second DA dose is based on the initial DA
dose and the change in Hb from the initial Hb.
Maintenance DA doses (dose 3 and thereafter)
are based on trend analysis of the most recent
Hb, the last two DA doses and any increase or
decrease in the last two doses with a target Hb
in the range of 10.5 – 12.5 g/dl. Using NKF
KDOQI-based parameters, CAMP© analyzes
monthly parameters of iron saturation, ferritin
and hemoglobin and recommends a form of
iron therapy (no iron, oral or i.v. iron). Simultaneously, CAMP© analyzes DA dose and Hb
trends and generates a DA dose recommendation. Dose escalations proceed in an algorithmic fashion also. DA doses are increased if Hb
declines or is stable but below goal for 2 consecutive months.
CAMP©-recommended DA doses were allocated only as total syringe (Aranesp Singleject™) – or unit vial-sized doses: 25, 40, 60,
100, 150, 200 and 300 μg. Supervising nephrol          UX|©
if there was an abrupt elevation or decline of
 $ } JP *     "  # 
$   } J~ *       * >lowing ascertainment of DA and iron dose(s),
CAMP© generates real-time procedural documentation that is forwarded electronically to
the healthcare provider for attestation.

%    $   
tion studied.
Characteristic
Gender
Male
Female
CKD Stage
Stage 3
Stage 4
Stage 5
Race
African-American
Caucasian
Other
Disease status
Diabetic: Yes
No
Protein- Yes
uric:
No
Diabetic and proteinuric
<#<
<#=
=#<
=#=

-

% of patients
*  ++/
45.9
54.1
41.4
37.6
21.1
62.4
33.1
4.5
54.2
45.8
45.7
54.3
31.0
22.5
14.7
31.8

Statistical methods
Data on hemoglobin, DA dose, ferritin and TSAT were collected at baseline, 3
months and 6 months into this study. Analysis of variance (ANOVA) for repeated measures was used for analysis as implemented

4
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 ++
Variable
Hb
DA dose
%&% *L/
Ferritin (Ln)
Ferritin
Geometric mean

%  ?
Mean
SD
10.02
0.70
96.39
40.21
23.10
9.64
4.93
1.08
138.12

       Month 3
Mean
SD
1.09
11.28a
109.06a 67.58
9.22
26.04a
4.93
0.94
138.36

Month 6
Mean
SD
11.31a
1.03
118.20a 90.95
29.78a,b 10.99
5.15
0.89
171.92a

"  "  #! %&%   $     &        !
  
 ! $  # ap < 0.05 vs. baseline parameter; bp <
0.05 3 month parameter vs. 6 month parameter.

Figure 2. Hemoglobin (Hb) distribution after 6
  $ 
  *=  ++/

" X ?[  \ >[ #  "
\ ?[   X >[ #

by PROC MIXED in SAS version 9.2 (SAS
Institute, Cary, NC, USA). This procedure
allows for incomplete data points to be used
in the analysis. Ferritin distribution was
highly skewed and log-transformed to provide a more normal distribution (Tables 2,
3, 4). Pairwise comparisons for all variables
were carried out with Hochberg’s method
applied to adjust for multiple testing. Additional parameters of diabetes and proteinuria
were added into repeated measures ANOVA
  $       =& 
In these designs, the two main effects of time
and diabetic status (or proteinuria status)
were tested for two-way interaction.

Results
Following application of exclusion criteria, data from 133 patients were analyzed,
and demographics are displayed in Table 1.
The average time from enrollment to administration of the sixth QM DA dose was 188
± 14 days.
The analysis of Hb (Table 2) revealed
    # $$   LLLJ"  
      #    
difference between baseline and 3-month
Hb levels that increased from 10.02 g/dl to
11.28 g/dl, p < 0.001. A similar relationship
was noted at 6 months, with Hb increasing to
11.31 g/dl (p < 0.001). Comparisons of Hb
  X  ~   ?      
The primary objective of the study was
to determine the proportion of patients that
achieved the target Hb range following 6
months of QM DA. At study end-point, 79.7%
$ &           
0.001). The remainder of subjects attained a
Hb lower than the target in 13.5% of cases
and a Hb exceeding 12.5 g/dl in 6.8% of cases
> &  '    $$   tected between baseline and 6-month values
$     LLL" _'_   LLLJ
  $
  LLJ _   
      $$  ~   ?  
TSAT was different in pairwise comparisons, with a steady increase from 23.1% to
?L    ?     LLLJ $
~   #&     LLLJ $ ?
months versus 3 months). Ferritin levels were
highly skewed (Table 2) and showed no sta       $   
3 months. However, the 6-month geometric
 $ JJ *     
higher than at 3 months (138.36 ng/ml).
The secondary objective of this trial
was to determine the effects of diabetes and
proteinuria on achieved Hb. An analysis of
     &        
impact of diabetes for any variable (Table 3).
The analysis of Hb over time followed the
   & # &"      cant interactions between time and diabetic
status. A parallel analysis by proteinuric status was also completed (Table 4), and a sig $$ $   &      
dose was found. Hemoglobin levels were
lower in patients with proteinuria and DA
doses were higher. An analysis of temporal
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% +

]$$ $               

Parameter
Hemoglobin
*#/

 */
%&% *L/

Ferritin (Ln)

% 
%  ?
Month 3
Month 6
%  ?
Month 3
Month 6
%  ?
Month 3
Month 6
%  ?
Month 3
Month 6

=   !  ^?
Mean
SD
10.12
0.69
0.97
11.28a
0.96
11.55a
92.00
41.04
71.76
109.50a
84.94
109.33a
24.32
10.81
26.42
10.69
12.68
31.03a
4.90
1.12
5.01
1.05
5.16
0.90

%&%   $    ! &        !   

% ` ]$$ $             
Parameter
Hemoglobin
*#/
  *//

%&% *L/

Ferritin (Ln)

% 
Baseline
3 months
6 months
Baseline
3 months
6 months
Baseline
3 months
6 months
Initial
3 months
6 months

= j   !
Mean
10.16
11.44a
11.62a
89.14
100.29
96.36
23.60
25.88a
30.47a
4.97
4.86
5.17

 _?
SD
0.60
0.89
0.82
33.65
64.80
75.89
9.90
9.26
11.10
1.03
1.02
0.92

%&%   $    ! &        !   
vs. non-proteinuric.

     && =  
  #"      
tions appeared. Lastly, the absolute values
and temporal changes in TSAT and serum
ferritin were not different between proteinuric and non-proteinuric patients.

Discussion
This study represents a single-center analysis of a computerized program, CAMP©,
that “treats” ESA-naïve patients with anemia of CKD in a real world setting. With this
automated clinical decision support system,
we evaluated the hypothesis that CKD Stage
3 – 5 patients could be successfully targeted
by QM DA therapy to the Hb range of 10.5 –
12.5 g/dl. The extension of the ESA dosing

  

  !
Mean
9.94
11.32a
11.15a
100.00
107.54a
120.56a
22.27
26.00
28.90a
5.02
4.91
5.18

 _
SD
0.71
1.18
1.02
40.00
64.97
92.19
8.70
7.78
9.25
1.01
0.82
0.87

 ap < 0.05 vs. Month 0.

 

     

j   !
Mean
9.83
11.14ab
10.97ab
105.42
119.07ab
139.41ab
22.78
26.32a
29.13a
4.94
5.03
5.15

 [q
SD
0.79
1.28
1.10
46.51
71.43
97.68
9.65
9.19
11.00
1.11
0.81
0.84

 ap < 0.05 vs. baseline, bp < 0.05

interval provides several advantages. Aside
from patient convenience and choice, with
a reduction of “out-of-pocket” expenses,
extended dosing intervals improve resource
utilization and reduce administrative paperwork and medicolegal documentation.
The expansion of healthcare provider time
garnered by reducing injections from onceweekly to once-monthly additionally provided greater opportunities for other medical
activities.
  $ $" UX|© achieved
the target Hb of 10.5 – 12.5 g/dl after 3 – 6
doses in nearly 80% of all patients treated
$  $ #   "   ~  
and 9.1% at 6 months). This result occurred
irrespective of the prior Hb and the degree
of pre-CAMP© iron repletion status and Hb

Chalhoub, Frinak, Zasuwa et al.

stability. This observation is in contradistinction to published QM DA trials. In fact, the
mean entry Hb of 10.0 g/dl was comparable
to that of other individuals initiated on RRT
[20]. Notably, the Hb versus time curve of
  & &    =   
90 – 150 days of therapy. The salutary nature
of prophylactic iron monitoring and delivery
by CAMP© &       evation of TSAT in treated subjects. In addition, the initial TSAT of 23.2% was lower
than the 28 – 32% levels cited in prior trials
in which ESAs were administered at twoweekly intervals [13, 14, 15, 16].
CAMP© was conceived of as a secure,
web-deployable, HIPAA-compliant decision support system for the anemia management. This program facilitated medicolegal
&         
providers regarding DA dosing, Hb levels
and ferrokinetic status. The CAMP©-based
DA prescription based on entry Hb rather
than bodyweight was selected because this
practice is more akin to real world-based
practice. In typical real world practice without automated decision support, healthcare
practitioners gauge the Hb response to ESA
 $      ~ ' 
Programmatic instillation of trend analysis into the CAMP© logic tree safeguarded
against “instinctive” reactions to alter the
DA dose solely predicated on the prevailing Hb level. Furthermore, the application
of synergistic, dually applied algorithms for
iron management and ESA dosing prevent  # $ 
&$  *
depletion during ESA-driven augmentation
of erythropoiesis. This “iron forward” approach was facile enough to identify patients
in whom oral iron failed to improve the fer    @    
&
in lieu of i.v. iron treatment with 500 – 1,000
mg of low molecular weight iron dextran.
Finally, because all data input was incorporated into a “back end” database, metrics at
the individual provider level could be readily
ascertained for continuous quality improvement. The institutional use of CAMP© generated a favorable response from patients,
improvements in resource allocation and
reduced prescribing variability by providers.
In our experience, the monthly injection and
documentation time per patient decreased by
nearly 84% from 60 to 7 minutes per patient

6
      "      cant differences among monitored variables
at any CKD stage throughout the observation
period.
In general, the diabetic condition is associated with enhanced expression of in=   & !"   #
of these markers have been correlated with
hyporesponsiveness to ESA therapy [23]. In
this study, we were unable to show statisti     $$    
diabetics and non-diabetics. By contrast,
proteinuria was associated with decreased
ESA responsiveness [24, 25, 26, 27] and may
# =     =  !
Proteinuric individuals manifested the worst
 & "        
DA doses.
One limitation of this analysis is its observational nature. CAMP© was not directly
compared to traditional, non-automated physician-driven, anemia management practices
in a randomized clinical trial. Such a prospective, randomized controlled trial, would
require the control of any iron replacement
    _$"     $ UX|©
as a clinical decision support system include
its prescription homogeneity, Hb and iron
parameter trend analysis, medicolegal documentation and time savings [29, 30].
In summary, automated QM DA administration to ESA-naïve patients successfully
treats the anemia of CKD in a real world
clinical setting and reduces the heterogeneity of treatment practice and responses. Concurrent algorithmic dosing of DA and iron,
orally or intravenously, prevents absolute
 $&           
balances the treatment of anemia of CKD
[29], even in a population where ferrokinetic
parameter interpretation may be insensitive,
       ~J" ~! @ 
advantages of computerized, programmatic
therapy include substantial reductions in
ESA delivery time, timely procedural documentation and improved patient satisfaction.
Lastly, CAMP© with its real-time database
collection and trend analysis of clinical data
facilitates continuous quality improvement
at individual and group provider levels. We
postulate that CAMP© will demonstrate sim $   '    
&   $    
~~"
34, 35, 36, 37, 38].
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